United States Drug Patent 8,778,999: Claim Scope, Expiration, Orange Book Exposure, and Generic Risk

US Patent 8,778,999 protects topical ophthalmic bromfenac compositions that combine a defined viscosity and pH profile with a flowable, crosslinked carboxy-containing polycarbophil mucoadhesive polymer. The strongest claim center is a bromfenac eye-drop formulation with viscosity of approximately 1,000 to 3,400 centipoise and pH of approximately 7.4 to 8.5. Dependent and independent claims extend coverage to combinations with ketorolac, other NSAIDs, steroids, antibacterial agents, and broad therapeutic uses.

The patent is formulation-focused. It does not broadly claim bromfenac as a molecule, bromfenac in every ophthalmic dosage form, or every use of bromfenac for ocular inflammation. Its practical enforcement value depends on whether a commercial product contains the claimed polycarbophil system and falls within the numerical viscosity, pH, and concentration limitations.

What does United States Patent 8,778,999 claim?

The patent claims four principal subject-matter groups:

Claim group	Claims	Principal limitation
Core bromfenac composition	1, 3, 4, 9-11	Bromfenac, flowable crosslinked carboxy-containing polycarbophil, viscosity and pH ranges
Combination compositions	2, 5-8, 12-15	Bromfenac combined with ketorolac, another NSAID, steroid, antibacterial or other active agent
Therapeutic methods	16-21	Administration to treat ocular inflammation and specified retinal or ophthalmic conditions
Narrow formulation embodiments	9-11	Viscosity of 1,000-2,000 cps, bromfenac of 0.01%-0.09%, and pH of approximately 8.3

Claim 1 is the principal composition claim. It requires all of the following:

A topical ophthalmic composition formulated for application to the eye.
A therapeutically effective amount of bromfenac.
A flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer.
Viscosity of approximately 1,000 to 3,400 cps.
pH of approximately 7.4 to 8.5.

A competing product that lacks the claimed polycarbophil polymer is outside claim 1 even if it contains bromfenac, is administered as eye drops, and has a similar pH. Conversely, a product using the claimed polymer may face infringement exposure even if it uses different preservatives, buffers, tonicity agents, or packaging, provided the remaining limitations are met.

How narrow is the core claim to bromfenac ophthalmic formulations?

The core claim is narrower than a typical active-ingredient claim but broader than a claim limited to one commercial formulation.

Required bromfenac component

Claims 1 and 3 do not specify a fixed bromfenac concentration. Claim 4 narrows the range to approximately 0.005% to 0.5% by weight. Claim 10 narrows it further to approximately 0.01% to 0.09% by weight.

The claim language appears broad enough to cover several ophthalmic bromfenac concentrations, including concentrations associated with commercial bromfenac products. But concentration alone does not establish infringement. The polymer, viscosity and pH limitations remain essential.

Required polycarbophil system

The polymer limitation is technically significant. The claims require a "flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer." A formulation using povidone, hydroxypropyl methylcellulose, carbomer, hyaluronic acid, or another viscosity-enhancing polymer may not satisfy this limitation unless the polymer is legally and technically equivalent to the claimed polycarbophil system.

The distinction between polycarbophil and generic carbomer-type polymers may become central in claim construction. Relevant questions include:

Whether the accused polymer is crosslinked.
Whether it contains carboxy groups in the claimed technical sense.
Whether it is a polycarbophil rather than another crosslinked polyacrylic-acid polymer.
Whether the polymer remains flowable at the claimed concentration.
Whether the polymer functions as a mucoadhesive in the accused formulation.

A supplier’s product description is not determinative. Chemical identity, crosslinking chemistry, molecular structure and formulation behavior would likely matter in an infringement dispute.

Viscosity and pH limitations

The numerical ranges create objective screening criteria:

Parameter	Broad claim range	Narrow dependent range
Viscosity	Approximately 1,000-3,400 cps	Approximately 1,000-2,000 cps
pH	Approximately 7.4-8.5	Approximately 8.3
Bromfenac concentration	No fixed limit in claim 1	Approximately 0.005%-0.5%; then 0.01%-0.09%

The word "about" introduces potential measurement and claim-construction issues. Viscosity can vary with temperature, spindle, shear rate, instrument and test protocol. A product may measure inside the range under one protocol and outside it under another. A technical assessment should therefore use the patent specification’s testing conditions, if stated, rather than a general quality-control measurement.

What formulations are protected by US 8,778,999?

The patent potentially covers the following formulation categories:

Bromfenac and polycarbophil

Claims 1, 3, 4 and 9-11 cover the base formulation. This is the commercially most important claim group because it does not require a second active ingredient.

Bromfenac and ketorolac

Claims 2, 7, 12 and 18 specifically address bromfenac-ketorolac combinations. Claim 12 is an independent composition claim requiring both actives, the polycarbophil polymer, drop-form administration, the viscosity range and the pH range.

A product containing both NSAIDs would face a more direct claim comparison than a product containing bromfenac alone. Claims 12 and 13 also reduce dependence on claim 1’s structure by reciting the combination and formulation elements directly.

Bromfenac and other NSAIDs

Claim 13 covers bromfenac with at least one additional NSAID, provided the polymer, viscosity, pH and drop-form limitations are satisfied. Claim 6 lists a long Markush group of NSAIDs, while claim 7 narrows the combination to ketorolac.

The broad list creates substantial nominal scope, but enforceability depends on written-description and enablement support across the listed compounds. A challenge could argue that the specification does not adequately teach every listed NSAID in the claimed high-viscosity ophthalmic system.

Bromfenac and corticosteroids

Claim 14 covers bromfenac with at least one steroidal anti-inflammatory agent. Claim 8 lists numerous corticosteroids, including dexamethasone, difluprednate, loteprednol etabonate, prednisolone and triamcinolone derivatives.

This claim group could reach postoperative combination products, but the formulation must still use the specified polymer and fall within the pH and viscosity ranges.

Bromfenac and antibacterial agents

Claim 15 covers bromfenac with at least one antibacterial agent. Claim 5 also includes antibacterial, antifungal, antiviral, antiallergic, glaucoma-treating and other agents.

These claims are broad in therapeutic category but remain formulation-limited. A product containing bromfenac and an antibiotic would not necessarily infringe unless the claimed polycarbophil, viscosity and pH requirements are present.

What methods of use does US 8,778,999 cover?

Claims 16-21 cover methods of treating inflammatory conditions of the eye by administering the claimed composition.

The method claims include:

Inflammation associated with surgical trauma.
Dry eye and allergic, viral or bacterial conjunctivitis.
Blepharitis and anterior uveitis.
Corneal injury, burns and foreign-body injury.
Ocular pain, redness, photophobia and swelling.
Corneal edema associated with cataract surgery.
Corneal transplantation and corneal ulcer.
Refractive surgery and phototherapeutic keratectomy.
Glaucoma, ocular tumors and oculoplastic procedures.
Retinal conditions, including diabetic macular edema, cystoid macular edema, retinal vascular disease, uveitis and age-related macular degeneration.

Claim 20 narrows the method to inflammation associated with a retinal condition. Claim 21 then lists specific retinal diseases and conditions.

The method claims do not eliminate the composition limitations. Administration of ordinary bromfenac drops for cataract-surgery inflammation would not satisfy these claims if the administered formulation lacks the claimed polycarbophil polymer, viscosity or pH.

The retinal claims may face practical scope issues. A topical eye-drop formulation must deliver a therapeutically effective amount to the relevant ocular tissue. For posterior-segment conditions such as retinal vein occlusion, diabetic macular edema or choroidal disease, enablement and written-description questions may become important if the patent’s examples focus mainly on topical anterior-segment treatment.

When does US Patent 8,778,999 lose exclusivity?

US 8,778,999 was issued on July 15, 2014. The patent’s ordinary expiration is determined by the earliest effective nonprovisional filing date in its priority chain, subject to patent-term adjustment, terminal disclaimer and any applicable patent-term extension.

The likely term framework is:

Event	Date or rule
Patent grant	July 15, 2014
Ordinary term	20 years from the earliest effective nonprovisional filing date
Patent-term adjustment	Added if awarded by the USPTO
Patent-term extension	Potentially available for qualifying regulatory review, subject to statutory limits
Terminal disclaimer	Could shorten the term if required during prosecution

A grant date does not determine the expiration date. The relevant public record is the patent’s continuity data and USPTO Patent Center term information. The patent number and claims supplied alone do not establish a legally reliable expiration date or any patent-term adjustment.

Any freedom-to-operate analysis should review continuations, divisionals, reissues and related patents. A patent can expire while a continuation with overlapping formulation claims remains enforceable.

What is the Orange Book status of bromfenac products?

Bromfenac is a small-molecule NSAID, so the relevant generic pathway is an abbreviated new drug application, not a biosimilar application. FDA-approved bromfenac ophthalmic products have included Bromday, Prolensa and generic bromfenac ophthalmic solutions.

Orange Book relevance depends on whether US 8,778,999 is listed against a specific approved NDA. A patent directed to a formulation or method of use can be Orange Book-listed if it meets the statutory listing requirements and claims the approved drug, its formulation, or an approved method of use. A platform patent that does not cover the approved product may not be properly listable.

The principal commercial distinction is between:

Patents listed against an approved NDA.
Unlisted patents that may still support infringement litigation.
Patents covering a product’s formulation but not its approved indication.
Patents covering a method of use that may be addressed through a section viii statement.

FDA’s Orange Book should be checked by NDA, active ingredient and patent number. A current Orange Book entry, if any, is more important for ANDA timing than the patent’s existence alone.[2]

Which companies are challenging bromfenac exclusivity?

Bromfenac generic competition is expected to come from companies filing ANDAs for ophthalmic bromfenac products. Public challenge analysis should distinguish between:

A filed ANDA with Paragraph IV certification.
A notice letter delivered to the NDA holder.
District-court litigation within 45 days.
A 30-month stay.
A final judgment, settlement or dismissal.
Commercial launch after invalidity, noninfringement, expiration or settlement.

A Paragraph IV challenge is not proof that a patent is weak. It is a certification that the applicant believes the listed patent is invalid, unenforceable or not infringed. The patent holder may file suit under 21 U.S.C. § 355(j)(5)(B)(iii), potentially triggering a 30-month stay of FDA approval.[3]

No specific challenger, Paragraph IV notice, litigation outcome or settlement agreement can be established from the claim text alone. Those events must be verified through FDA ANDA records, PACER, district-court dockets, SEC filings and Orange Book updates.

How strong is the patent estate for bromfenac ophthalmic products?

US 8,778,999 has moderate potential strength as a formulation patent and weaker apparent breadth as a general bromfenac patent.

Strengths

Claim 1 combines multiple measurable limitations.
The polymer limitation can distinguish ordinary bromfenac solutions.
Claims 9-11 provide narrower fallback positions.
Claims 12-15 directly recite several combination-product configurations.
The method claims cover a broad range of ocular conditions.
Viscosity and pH provide objective infringement criteria.

Vulnerabilities

The patent does not claim bromfenac generally.
A competing product may design around the polycarbophil limitation.
A non-viscous or lower-viscosity solution may avoid the claims.
The broad Markush lists may invite written-description and enablement challenges.
"About" ranges may create measurement disputes.
The therapeutic-effectiveness requirement can complicate proof for broad disease lists.
The retinal method claims may be vulnerable if the specification lacks representative data for posterior-segment diseases.

The most defensible claims are likely the narrower embodiments that combine a specifically identified bromfenac concentration with pH near 8.3 and viscosity within the narrower range, assuming the specification supports those parameters with examples.

How does US 8,778,999 compare with commercial bromfenac products?

Product or category	Active ingredient	Typical formulation distinction	Relevance to US 8,778,999
Bromday	Bromfenac ophthalmic solution	Bromfenac 0.09% solution	Requires proof of claimed polycarbophil and viscosity profile
Prolensa	Bromfenac ophthalmic solution	Bromfenac 0.07% solution	Product label and composition must be compared with every claim limitation
Generic bromfenac	Bromfenac ophthalmic solution	ANDA-based equivalent or permitted formulation	Paragraph IV and design-around risk depend on Orange Book listings
Combination product	Bromfenac plus ketorolac, steroid or antibiotic	Two-active formulation	Claims 12-15 are the principal exposure points

Product names do not establish infringement. The critical evidence is the approved formulation, inactive-ingredient list, technical viscosity data and pH specification.

What generic launch scenarios exist?

Early Paragraph IV launch

A first applicant may challenge the patent and pursue approval before expiration. Launch risk would increase if the product avoids the polycarbophil limitation or if the patent is held invalid or not infringed.

Section viii carve-out

If only a method-of-use claim is listed, an ANDA applicant may omit the patented indication while seeking approval for unprotected uses. This route does not automatically avoid formulation claims.

Post-expiration entry

A generic can enter after all relevant patents and regulatory exclusivities expire, subject to FDA approval and any surviving continuation patents.

Formulation design-around

The clearest design-around strategies are:

Use a different mucoadhesive polymer.
Use a non-mucoadhesive viscosity modifier.
Keep viscosity below 1,000 cps.
Use a pH outside the claimed range where product stability and tolerability permit.
Use bromfenac without the claimed additional active agent.
Avoid the claimed combination of bromfenac and ketorolac.

Each strategy must be evaluated against the doctrine of equivalents. A change that preserves substantially the same function, way and result may still create litigation risk, although numerical and chemical limitations often provide stronger design-around opportunities than purely functional language.

What manufacturing and intellectual-property barriers remain?

The polymer system may create manufacturing barriers even if patent coverage is avoided. High-viscosity ophthalmic drops require control of:

Sterile processing and aseptic filling.
Polymer hydration and dispersion.
Batch-to-batch viscosity.
pH drift during storage.
Drop size and dosing uniformity.
Filterability and preservative compatibility.
Container closure performance.
Ocular comfort and blurred-vision effects.

A generic sponsor also must compare inactive ingredients, stability, delivery performance and bioequivalence requirements under FDA’s ophthalmic drug framework. Manufacturing know-how may remain valuable after patent expiration if the formulation depends on difficult polymer processing or narrow rheological specifications.

What revenue exposure is associated with this patent?

The relevant revenue exposure is the sales of products whose actual formulation practices fall within the claims, not all bromfenac sales. Exposure should be segmented by:

Product and NDA.
Bromfenac concentration.
Polymer system.
Viscosity specification.
Approved indication.
Geographic market.
Remaining patent term.
Probability and timing of generic entry.

Because US 8,778,999 is formulation-specific, a company’s entire bromfenac franchise would not automatically be at risk. The highest exposure would arise from a product using crosslinked carboxy-containing polycarbophil at the claimed viscosity and pH.

Key Takeaways

US 8,778,999 is principally a formulation patent for bromfenac ophthalmic compositions.
Claim 1 requires bromfenac, a flowable crosslinked carboxy-containing polycarbophil, viscosity of approximately 1,000-3,400 cps and pH of approximately 7.4-8.5.
Claims 12-15 extend coverage to bromfenac combinations with ketorolac, other NSAIDs, steroids and antibacterial agents.
Claims 16-21 cover treatment of broad ocular and retinal inflammatory conditions but remain tied to the claimed composition.
The principal design-around path is use of a different polymer or a formulation outside the viscosity or pH ranges.
Bromfenac is a small molecule, so generic challenges proceed through ANDAs and Paragraph IV certifications rather than biosimilar applications.
Orange Book listing and current expiration status cannot be determined from the claim text alone.
Commercial infringement exposure depends on the actual approved formulation and analytical testing, not the product name or active ingredient alone.

FAQs

Is US 8,778,999 a patent on bromfenac itself?

No. It claims specified ophthalmic compositions and treatment methods. It does not broadly claim the bromfenac molecule.

Can a bromfenac product infringe without containing ketorolac?

Yes. Claim 1 and related dependent claims cover bromfenac compositions without ketorolac if the required polycarbophil, viscosity and pH limitations are satisfied.

Does using carbomer instead of polycarbophil avoid infringement?

Not automatically. Chemical identity and claim construction would determine whether the polymer falls within the literal claim or is equivalent to the claimed polycarbophil.

Are retinal uses automatically covered by the patent?

No. The administered composition must meet the applicable composition limitations. The method claims also require treatment of the specified inflammatory condition.

Does FDA approval confirm that a generic is outside US 8,778,999?

No. FDA approval and patent infringement are separate issues. A generic may receive approval after a Paragraph IV certification, a section viii statement, patent expiration or a settlement arrangement.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,778,999, ophthalmic composition and therapeutic treatment claims.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (n.d.). Bromfenac ophthalmic drug product labeling for approved ophthalmic solutions.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, patent term and claim construction provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2753947	⤷ Start Trial
Denmark	2403493	⤷ Start Trial
European Patent Office	2403493	⤷ Start Trial
Spain	2586064	⤷ Start Trial
Portugal	2403493	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2010102192	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,778,999

Summary for Patent: 8,778,999